Cargando…
The cerebrospinal fluid biomarker ratio Aβ42/40 identifies amyloid positron emission tomography positivity better than Aβ42 alone in a heterogeneous memory clinic cohort
BACKGROUND: Cerebrospinal fluid (CSF) analysis for detecting amyloid positivity may be as reliable as positron emission tomography (PET). We evaluated the performance of the amyloid beta (Aβ)42/40 ratio for predicting amyloid positivity by PET, compared with Aβ42 alone, and phosphorylated tau 181 (p...
Autores principales: | Amft, Michaela, Ortner, Marion, Eichenlaub, Udo, Goldhardt, Oliver, Diehl-Schmid, Janine, Hedderich, Dennis M., Yakushev, Igor, Grimmer, Timo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9044878/ https://www.ncbi.nlm.nih.gov/pubmed/35473631 http://dx.doi.org/10.1186/s13195-022-01003-w |
Ejemplares similares
-
Correction to: Amyloid PET, FDG-PET or MRI? - the power of different imaging biomarkers to detect progression of early Alzheimer’s disease
por: Ortner, Marion, et al.
Publicado: (2020) -
Elecsys Cerebrospinal Fluid Immunoassays Accurately Detect Alzheimer’s Disease Regardless of Concomitant Small Vessel Disease
por: Ortner, Marion, et al.
Publicado: (2023) -
Distributions of Aβ42 and Aβ42/40 in the Cerebrospinal Fluid in View of the Probability Theory
por: Lewczuk, Piotr, et al.
Publicado: (2021) -
Cerebrospinal fluid lactate levels along the Alzheimer’s disease continuum and associations with blood-brain barrier integrity, age, cognition, and biomarkers
por: Zebhauser, Paul Theo, et al.
Publicado: (2022) -
Cerebrospinal Fluid Aβ(42/40) Corresponds Better than Aβ(42) to Amyloid PET in Alzheimer’s Disease
por: Lewczuk, Piotr, et al.
Publicado: (2016)